Home Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices
 

Keywords :   


Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices

2013-10-24 16:27:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the companys investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Imraan Munshi, (215) 652-0059Investor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: update committee practices advisory

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
06.11Hurricane Rafael Update Statement
06.11Summary for Hurricane Rafael (AT3/AL182024)
06.11Warning millions will struggle to pay water bill rises
06.11Atlantic Tropical Weather Outlook
06.11Tropical Storm Rafael Graphics
06.11Tropical Storm Rafael Public Advisory Number 9A
06.11Summary for Tropical Storm Rafael (AT3/AL182024)
06.11Eastern North Pacific Tropical Weather Outlook
More »